Skip to main content
Premium Trial:

Request an Annual Quote

Molzym Gets CE Mark for Sepsis PCR Test

NEW YORK (GenomeWeb News) – German firm Molzym has received the CE Mark for its PCR-based test for sepsis enabling the firm to market the test throughout the European Union.
 
Molzym’s SepsiTest detects more than 345 relevant sepsis pathogens and can provide results in less than four hours. The firm claims that it is the first PCR-based assay that can detect all of the relevant strains in one test.
 
“Broad-spectrum molecular sepsis diagnostics will for the first time enable early targeted treatments and SepsiTest will greatly support clinicians in their bedside decision-making,” Michael Lorenz, chief scientist at Bremen, Germany-based Molzym, said in a statement.